Frédéric Rolland - Concepedia

Author

Frédéric Rolland

Also Known As

Eric Voog, F ROLLAND, F Rolland, F. ROLLAND, F. Rolland, Frederic ROLLAND, Frederic Rolland, Fréderic Rolland, Frédéric ROLLAND, Frédéric Rolland

250

Publications

23.4K

Citations

H-Index

Concepts

All Affiliations

Institut Gustave Roussy Institut de Cancérologie de l'Ouest Centre Léon Bérard Institut Paoli-Calmettes Centre Eugène Marquis

About

Frédéric Rolland is an author at Institut Gustave Roussy specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	77	7.5K
2	Health Sciences	15	20	987
3	Cell Biology	3	3	276
4	Education	2	2	126
5	Clinical Immunology	1	1	13

Frédéric Rolland

114

Publications

22.6K

Citations

H-Index

Page 1

	Year	Citations
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Bernard Escudier, Tim Eisen, Walter M. Stadler, New England Journal of Medicine	2007	4.8K
Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer Jacques Bernier, C. Domenge, Mahmut Özsahin, New England Journal of Medicine	2004	3.1K
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, New England Journal of Medicine	2021	1.7K
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, The Lancet MedicinePathologyHead And Neck CancerCancer TreatmentNeck Oncology	2018	1.6K
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial Bernard Escudier, Tim Eisen, Walter M. Stadler, Journal of Clinical Oncology	2009	1.1K
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy Jan B. Vermorken, José Trigo, Ricardo Hitt, Journal of Clinical Oncology	2007	996
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma Arnaud Méjean, Alain Ravaud, Simon Thézenas, New England Journal of Medicine	2018	909
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Gwénaëlle Gravis, Karim Fizazi, Florence Joly, The Lancet Oncology Androgen-deprivation TherapyUrologyGenitourinary CancerMedicineGetug-afu 15	2013	727
Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma Bernard Escudier, Cezary Szczylik, Thomas E. Hutson, Journal of Clinical Oncology	2009	489
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial Gwénaëlle Gravis, Jean‐Marie Boher, Florence Joly, European Urology UrologyGenitourinary CancerGetug-afu15 TrialMedicineAndrogen Deprivation Therapy	2015	454

Page 1